Skip to main content

Fettstoffwechsel der Niere als Therapieziel

Kidney lipid metabolism as a therapeutic target

This is a preview of subscription content, access via your institution.

Literatur

  1. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845

    CAS  Article  Google Scholar 

  2. Wen H, Kumar V, Lan X, Shoshtari SSM, Eng JM, Zhou X, Wang F, Wang H, Skorecki K, Xing G, Wu G, Luo H, Malhotra A, Singhal PC (2018) APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. Biosci Rep 38:BSR20171713

    Article  Google Scholar 

  3. Chun J, Zhang JY, Wilkins MS, Subramanian B, Riella C, Magraner JM, Alper SL, Friedman DJ, Pollak MR (2019) Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. Proc Natl Acad Sci U S A 116:3712–3721

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kai-Dietrich Nüsken.

Ethics declarations

Interessenkonflikt

K.-D. Nüsken gibt an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

Thorsten Feldkamp, Rendsburg-Eckernförde

Jens Lutz, Koblenz

Lutz T. Weber, Köln

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nüsken, KD. Fettstoffwechsel der Niere als Therapieziel. Nephrologie 17, 261–262 (2022). https://doi.org/10.1007/s11560-022-00580-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-022-00580-z